In this case report, we examine an advanced technique for renal denervation (RDN)—ultrasound energy—employed to manage severe hypertension in patients with complex medical histories.

In this case report, we examine an advanced technique for renal denervation (RDN)—radiofrequency energy—employed to manage severe hypertension in patients with complex medical histories.

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Charles Fauvel provides his take on the RELIEVE-HF study outcomes presented by Gregg W. Stone at ACC.24 in Atlanta.

Large-bore femoral access closure remains a critical step in transfemoral TAVI, where access-site complications can significantly impact outcomes.

This My Toolkit article presents a step-by-step tutorial on a combined suture- and plug-based closure strategy using one ProStyle™ and one Angio-Seal®. The technique aims to achieve rapid, reliable...

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022. 

Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Transcatheter interventions have rapidly reshaped the management of tricuspid valve disease, with landmark trials establishing feasibility and early clinical benefit.

Beyond these pivotal studies, a series of less visible but highly informative papers addressed mechanisms, complications, patient phenotypes, and unintended consequences of intervention.

This curated selection highlights ten impactful tricuspid...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)